102 related articles for article (PubMed ID: 38831540)
1. Exploring the Molecular Therapeutic Mechanisms of Gemcitabine through Quantitative Proteomics.
Jiang Y; Ren X; Zhao J; Liu G; Liu F; Guo X; Hao M; Liu H; Liu K; Huang H
J Proteome Res; 2024 Jun; ():. PubMed ID: 38831540
[TBL] [Abstract][Full Text] [Related]
2. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
3. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Lin Q; Shen S; Qian Z; Rasam SS; Serratore A; Jusko WJ; Kandel ES; Qu J; Straubinger RM
Mol Cell Proteomics; 2022 Oct; 21(10):100409. PubMed ID: 36084875
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
Chen YW; Liu JY; Lin ST; Li JM; Huang SH; Chen JY; Wu JY; Kuo CC; Wu CL; Lu YC; Chen YH; Fan CY; Huang PC; Law CH; Lyu PC; Chou HC; Chan HL
Mol Biosyst; 2011 Nov; 7(11):3065-74. PubMed ID: 21894339
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
[TBL] [Abstract][Full Text] [Related]
6. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
8. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
9. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity.
Kong R; Qian X; Ying W
Sci Data; 2022 Jun; 9(1):283. PubMed ID: 35680938
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide inhibits Skp2 expression to increase chemosensitivity to gemcitabine in pancreatic cancer cells.
Gao J; Wang G; Wu J; Zuo Y; Zhang J; Chen J
Am J Transl Res; 2019; 11(2):991-997. PubMed ID: 30899398
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
[No Abstract] [Full Text] [Related]
15. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
[TBL] [Abstract][Full Text] [Related]
16. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway.
Rasam S; Lin Q; Shen S; Straubinger RM; Qu J
J Proteome Res; 2023 Dec; 22(12):3780-3792. PubMed ID: 37906173
[TBL] [Abstract][Full Text] [Related]
17. Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Kushwah V; Agrawal AK; Dora CP; Mallinson D; Lamprou DA; Gupta RC; Jain S
Pharm Res; 2017 Nov; 34(11):2295-2311. PubMed ID: 28795274
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Fujiwara-Tani R; Sasaki T; Takagi T; Mori S; Kishi S; Nishiguchi Y; Ohmori H; Fujii K; Kuniyasu H
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887170
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]